ReviewFrontiers in immunology2019
Autoantibodies in Morphea: An Update.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- A linear indurated forehead lesion with scalp alopecia.JAAD case reports · 2026Article
- Plastic Surgery Interventions for Localized Scleroderma Deformities: an Evidence Synthesis.Aesthetic plastic surgery · 2025Review
- Sclerosing diseases of the skin.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- Anti-synthetase and myelodysplastic syndromes with deep morphea: an example of shared immunopathogenesis? A case-based review.Rheumatology international · 2024Review
- Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma.International journal of molecular sciences · 2024Article
- Advances in the Management of Localized Scleroderma: A Systematic Review of Laser Therapy and Injectable Filler Approaches.Journal of personalized medicine · 2024Review
- The Serological Evidence of Positive Rheumatoid Factor in Morphea Patients and Its Relation to Disease Severity.Cureus · 2024Article
- Biomarkers in skin autoimmunity-An update on localised scleroderma.Skin health and disease · 2024Review
- A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-Onset Patients Diagnosed With Localized Scleroderma.Dermatology practical & conceptual · 2024Article
- Article
- Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.Clinical reviews in allergy & immunology · 2023Article
- Localized scleroderma with pulmonary arterial hypertension and pulmonary interstitial fibrosis in a patient with positive Th/to antibodies: Case report and review of literature.Clinical case reports · 2023Article
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
- Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial.Pharmaceutics · 2022Article
- Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection.Clinical case reports · 2022Article
- Not every white spot is vitiligo.Paediatrics & child health · 2022Article
- Morphea Profunda with Tertiary Lymphoid Follicles: Description of Two Cases and Review of the Literature.Dermatopathology (Basel, Switzerland) · 2022Article
- The Immunogenetics of Morphea and Lichen Sclerosus.Advances in experimental medicine and biology · 2022Review
- Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases.Clinical, cosmetic and investigational dermatology · 2022Review
- Upcoming treatments for morphea.Immunity, inflammation and disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin autoimmune conditions belong to a larger group of connective tissue diseases and primarily affect the skin, but might also involve underlying tissues, such as fat tissue, muscle, and bone. Autoimmune antibodies (autoantibodies) play a role in autoimmune skin diseases, such as localized scleroderma also termed morphea, and systemic scleroderma, also called systemic sclerosis (SSc). The detailed studies on the biological role of autoantibodies in autoimmune skin diseases are limited. This results in a few available tools for effective diagnosis and management of autoimmune skin diseases. This review aims to provide an update on the detection and most recent research on autoantibodies in morphea. Several recent studies have indicated the association of autoantibody profiles with disease subtypes, damage extent, and relapse potential, opening up exciting new possibilities for personalized disease management. We discuss the role of existing autoantibody tests in morphea management and the most recent studies on morphea pathogenesis. We also provide an update on novel autoantibody biomarkers for the diagnosis and study of morphea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.